Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Tiumbio.

    Client Virtual Booth

    TIUMBIO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Tiumbio
    korearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    4F, 49, Daewangpangyo-ro 644beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13493
    Telephone
    Telephone
    031-600-1500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.tiumbio.com/en/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

    Details:

    TU7710, a novel recombinant activated factor VII (rFVIIa) for hemophilia patients with inhibitors. It is being evaluated in the Phase I clinical trial studies for the treatment of Hemophilia A & B and also Blood Coagulation Disorders.


    Lead Product(s): TU7710

    Therapeutic Area: Genetic Disease Product Name: TU7710

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 26, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    TiumBio Secures KRW 38.5 Billion in Anticipation of Upcoming Clinical Data

    Details:

    The proceeds will be primarily allocated to support TiumBio's clinical programs that include a Phase 2 trial of TU2670 (merigolix), a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in endometriosis.


    Lead Product(s): Merigolix

    Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: TU2670

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: SK Chemicals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Private Placement December 29, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China

    Details:

    TU2670 is an orally active non-peptide GnRH antagonist currently undergoing a Phase 2a clinical study in the EU for the treatment of moderate to severe pain associated with endometriosis.


    Lead Product(s): HS-10518

    Therapeutic Area: Neurology Product Name: TU2670

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Hansoh Pharma

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates

    Details:

    Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.


    Lead Product(s): Nanocyclix Drug Candidates

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Oncodesign

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration October 21, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search